[3-[2-(3-Methylphenyl)ethyl]pyridin-2-yl]-(1-methylpiperidin-4-yl)methanone | 130642-52-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [3-[2-(3-Methylphenyl)ethyl]pyridin-2-yl]-(1-methylpiperidin-4-yl)methanone
• CAS: 130642-52-3
• 化学式: C₂₁H₂₆N₂O
• 分子量: 322.45
• InChiKey: CIAGAOWUUTXPPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [3-[2-(3-Methylphenyl)ethyl]pyridin-2-yl]-(1-methylpiperidin-4-yl)methanone 在 三氟甲磺酸 作用下， 生成 13-Methyl-2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
  参考文献：
  名称：

  血小板活化因子和组胺的双重拮抗剂。鉴定N-酰基-4-（5,6-二氢-11H-苯并[5,6]环庚-[1,2-b]吡啶-11-亚吡啶）哌啶的双重活性的结构要求。

  摘要：

  DOI：

  10.1021/jm00105a069
• 作为产物：
  描述：

  3-甲基苄基氯 在 盐酸 、 正丁基锂 、 三氯氧磷 作用下， 生成 [3-[2-(3-Methylphenyl)ethyl]pyridin-2-yl]-(1-methylpiperidin-4-yl)methanone
  参考文献：
  名称：

  血小板活化因子和组胺的双重拮抗剂。鉴定N-酰基-4-（5,6-二氢-11H-苯并[5,6]环庚-[1,2-b]吡啶-11-亚吡啶）哌啶的双重活性的结构要求。

  摘要：

  DOI：

  10.1021/jm00105a069

文献信息

• PIWINSKI, JOHN J.;WONG, TESSE K.;GREEN, MICHAEL J.;GANQULY, ASHIT K.;BILL+, J. MED. CHEM., 34,(1991) N, C. 457-461
  作者：PIWINSKI, JOHN J.、WONG, TESSE K.、GREEN, MICHAEL J.、GANQULY, ASHIT K.、BILL+

  DOI：——

  日期：——
• PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE)
  申请人：CANNATA Vincenzo

  公开号：US20090005567A1

  公开（公告）日：2009-01-01

  A process and new oxazolinic intermediates for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-clohepta-[1,2-b]-pyridin-11-ylide-ne)-1-piperidinecarboxylic acid ethyl ester (loratadine) is described. The process starts from 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine, a new intermediate to obtain loratadine. 2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-3-methyl-pyridine is condensed with 3-chloro-benzyl-chloride and the resultant product is treated with Grignard reagent of 4-chloro-N-methyl-piperidine. [3-(2-(3-chloro-phenyl)-ethyl]-pyridin-2-yl-]-1-(methyl-piperidin-4-yl)-methanone is obtained for subsequent hydrolysis. Starting from this last compound it is possible to obtain loratadine with known methods.
• Dual antagonists of platelet-activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines
  作者：John J. Piwinski、Jesse K. Wong、Michael J. Green、Ashit K. Ganguly、M. Motasim Billah、Robert E. West、William Kreutner

  DOI：10.1021/jm00105a069

  日期：1991.1